Aytu生物药厂发射EXXUA,这是林业发展局批准的第一个5HT1的成人抑郁症抗药剂师,已证明是有效的,试验中没有性功能障碍或体重增加。 Aytu BioPharma launches EXXUA, the first FDA-approved 5HT1a agonist for adult depression, with proven efficacy and no sexual dysfunction or weight gain in trials.

Aytu BioPharma在美国推出了EXXUA(gepirone)延长释放片片,这是林业发展局批准的第一个用于成人严重抑郁症的5HT1激动剂。 Aytu BioPharma has launched EXXUA (gepirone) extended-release tablets in the U.S., the first FDA-approved 5HT1a agonist for adult major depressive disorder. 它通过Aytu RxConnect和主要批发商提供,表明在5 000多名病人的试验中,症状显著改善,没有报告与安慰剂相比,性功能失调或体重增加。 Available through Aytu RxConnect and major wholesalers, it shows significant symptom improvement in trials with over 5,000 patients, with no reported sexual dysfunction or weight gain versus placebo. 未经儿童批准,它携带箱式警告,警告年轻成年人自杀风险增加。 Not approved for children, it carries a boxed warning for increased suicidal risk in young adults. 过敏者不应在长时间的QTc间隔、强大的CYP3A4抑制剂上或停止MAOI后14天内使用。 It should not be used by those allergic to it, with prolonged QTc intervals, on strong CYP3A4 inhibitors, or within 14 days of stopping an MAOI. Aytu的准入方案旨在确保可负担性和广泛可用性。 Aytu’s access program aims to ensure affordability and broad availability. 更多详情见EXXUA.com网站。 More details at EXXUA.com.